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Summary Platinum based combination chemotherapy has been associated with a high response rate in
patients with cervical carcinoma. To determine whether the toxicity could be reduced but the efficacy
maintained carboplatin 200mgim-2 was substituted for cisplatin in a regimen that was repeated two weekly
and also contained vincristine, methotrexate and bleomycin.
Twenty-four patients with squamous cell carcinoma of the cervix of whom 17 had relapsed following
radiotherapy were studied. Only 5 of the 19 evaluable patients had a partial response (26%, 95 confidence
limits 45.7-6.3%) compared to 30 of 43 (70%, 84-56%) who received a cisplatin combination in a previous
study (P<0.01) (Rustin et al., 1987). Carboplatin as given in the COMB regimen appears less effective than
cisplatin containing combinations for squamous cell carcinoma of the cervix.
In a previous study we observed a response rate of 71% in
24 patients with advanced squamous cell carcinoma of the
cervix using a combination of cisplatin, vincristine, metho-
trexate, and bleomycin (POMB) (Rustin et al., 1987).
Extension of this study to 43 evaluable patients has resulted
in a response rate of 70% (personal observation). Similar
response rates have been reported using other combinations
which include cisplatin and bleomycin (Rosenthal et al.,
1983; Kirsten et al., 1987; Daghestani et al., 1983; Bloch
et al., 1984). The major toxicity of these combinations has
been due to the cisplatin.
The platinum analogue carboplatin has been shown in
phase 1 and 2 studies to cause less nausea, vomiting and
nephrotoxicity than cisplatin (Calvert et al., 1982; Wiltshaw
et al., 1985; Canetta et al., 1985). A response rate of 28%
was observed in 39 patients with squamous cell carcinoma of
the cervix treated with carboplatin (Arsenau et al., 1986)
which is similar to responses of 21 to 31% observed
following different schedules of cisplatin. We therefore
substituted carboplatin for cisplatin in the POMB regimen
and determined the activity and toxicity of this 'COMB'
regimen in patients with squamous cell carcinoma of the
cervix.
Patients and methods
COMB was given to 24 consecutive patients with squamous
cell carcinoma of the cervix with characteristics shown in
Table I. Responses to chemotherapy were assessed according
to WHO criteria at a minimum of 28 days following the first
course of therapy. COMB chemotherapy was given as
follows:
Day 1. Bleomycin 10mg in 1 ml 1% lignocaine intra-
muscularly, vincristine 1.0mgm-2, methotrexate 300mgm-2
as a 12h infusion in 11 0.9% sodium chloride with 15mg
folinic acid rescue at 24, 36, 48, and 60h.
Day 2. Bleomycin injections repeated at 06.00 and 18.00h.
Carboplatin 200mgm-2 in 500ml of 5% dextrose as a 1 h
infusion.
Treatment was repeated after a 12 day drug free interval
provided that the total white blood count was >2 x 1091-
and platelet count was >100 x 1091-1. Dose modifications
consisted of omitting methotrexate in the patient with a
pleural effusion and the 4 patients with an EDTA clearance
of <40mlmin-1 and reducing the dose by between 50%
and 80% in 3 other patients with less serious impairment of
renal function. The dose of carboplatin was reduced to 75%
in the 4 patients with EDTA clearance of less than
40mlmin-.
Results
Five patients were not evaluable, three because of early
deaths. One who had pain control after the first course died
from uncontrollable bleeding from the bladder after the
second course despite a normal platelet count. A second
patient had no improvement of her hypercalcaemia after the
first course and died whilst neutropenic, 10 days after the
second course in which the dose of carboplatin and metho-
trexate had been reduced to 70% and 33% respectively. A
third patient who had normal renal function prior to
therapy, died from a neutropenic septicaemia 16 days after
her first course of full dose COMB.
There were no complete responses and only 5 (26%) of the
remaining 19 patients had a partial response (95% confi-
dence limits 45.7-6.3%). The duration of responses were 3,
3, 4, and 18 months, and 2+ months in a woman who had
responding iliac nodes surgically removed. Six patients had
progression of tumour whilst on COMB and in 8 patients
there was no change.
Table I Patient characteristics
Number of patients
Median age
Performance staus (ECOG)
Prior radiotherapy
Prior chemotherapy
Sites of disease
Pelvis
Supraclavicular nodes
Liver
Bone+pleural effusion
Dose modification
Courses of chemotherapy
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24
46 (26-67)
0-6
1-6
2-8
3-4
17
0
23
3
2
1
8
1-2
2-8
3-2
4-10
>5-2
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Nausea and vomiting was only severe (WHO grade 4) in 3
patients receiving COMB. Partial alopecia was apparent in
most patients. Haematological toxicity is shown in Table II.
Delays in chemotherapy due to myelosuppression occurred
in 2 of 8 patients who had 2 courses, and in 2 of 14 having 3
or more courses.
Table II Haematological toxicity
WHO grade
0 1 2 3 4
Haemoglobin 4 5 7 6 2
Leucocytes 4 4 7 5 4
Platelets 20 0 1 1 2
Discussion
This study was terminated when analysis demonstrated a
response rate of only 26% (95% confidence limits 6.3-
45.7%). This compared with a response rate of 70% (95%
confidence limits 56-84%) in our previous study (Rustin et
al., 1987 & personal observation) where cisplatin was used in
the POMB combination (Yates corrected chi square=8.43;
P<0.01). The only obvious difference in patient charac-
teristics between the two studies was that no patients who
received COMB had lung metastases whilst they were
present in 7 of 43 patients who received POMB, of whom
71% with lung metastases responded. A similar percentage
of patients in the two studies had a low performance status
of WHO grade 3 or 4 (COMB 16%, POMB 25%). Although
more patients receiving COMB than POMB had been given
prior radiotherapy (63% vs. 58%) those 22 receiving POMB
still had a response rate of 73%. Due to the small number of
patients, the response rate data in the present study could
have been biased by other unrecognised poor risk factors
and should be treated with caution.
Chemotherapy was only delayed because of myelo-
suppression in 2 of 12 patients who received 3 or more
courses. This suggests that cumulative myelosuppression was
not a problem of the two weekly regimen despite the phase 1
studies of carboplatin indicating that the platelet nadir was
at about day 21 (Calvert et al., 1982). Although neutropenic
septicaemia was the probable cause of death in two patients,
it is possible that methotrexate was the cause of this toxicity
considering the small dose of carboplatin that these two
patients received.
Carboplatin and cisplatin appear to have equal anti-
tumour activity as single agents against ovarian carcinoma
(Wiltshaw, 1985; Canetta et al., 1985), but recent data
suggest that carboplatin may be less effective than cisplatin
against cervical carcinoma (McGuire et al., 1988; Bonomi et
al., 1985). This probably explains the low response rate of
COMB. An alternative explanation is that the lower peak
serum concentrations after giving 200mgm-2 carboplatin 2
weekly rather than 400mgm-2 4 weekly results in a reduced
anti-tumour effect although the total dose is the same. The
low response rate and occasional severe myelosuppression
has led us to cease using carboplatin containing combin-
ations in patients with carcinoma of the cervix.
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